GlassScriptPhysician profile
Thomas J Byrd
NPI 1326011792
$15,802.64
in general payments reported to CMS, 2019-2025
28 companies · $3,988 in 2025
The $3,988 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,355 · 2020: $900 · 2021: $1,311 · 2022: $657 · 2023: $882 · 2024: $711 · 2025: $3,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775 · Travel and Lodging: $2,685 · Entertainment: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.42 |
| Travel and Lodging | $2,684.91 |
| Entertainment | $120.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,721.57 | 2019-2021 | |
| Smith+Nephew, INC. | $3,820.20 | 2019-2025 | Q-Fix, Healicoil, Bone Anchors With Arthroscopic Delivery System |
| Alcon Vision LLC | $1,975.93 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Aerie Pharmaceuticals, INC. | $756.88 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $539.19 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $265.05 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $231.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $195.87 | 2019-2023 | |
| Oyster Point Pharma, INC. | $174.12 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $170.04 | 2025 | Xdemvy |
| Abbvie INC. | $153.60 | 2022-2025 | Lumigan, Vuity |
| Apellis Pharmaceuticals, INC. | $121.29 | 2025 | Syfovre |
| Optos, INC. | $120.10 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $66.27 | 2019-2024 | Omni Surgical System |
| New World Medical,INC. | $62.86 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $62.16 | 2019 | |
| Kala Pharmaceuticals, INC. | $58.76 | 2021 | |
| Biotissue Holdings INC. | $57.41 | 2024-2025 | |
| Rxsight INC | $40.03 | 2022-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Dompe US, INC. | $39.30 | 2021 | |
| Ocular Therapeutix, INC. | $38.22 | 2024 | Dextenza |
| Rayner Intraocular Lenses Limited | $25.47 | 2024 | Rayone Spheric, Rayone Emv, Rayner Cataract Set 1 |
| Thea Pharma INC. | $21.81 | 2025 | Iyuzeh |
| Amgen INC. | $20.40 | 2024 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Beaver-Visitec International, INC. | $19.08 | 2021 | |
| Pinnacle, INC | $13.92 | 2023 | |
| Horizon Therapeutics Plc | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.